Assessment of osteopontin in early breast cancer: Correlative study in a randomised clinical trial

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Bramwell, Vivien H C ^a   Tuck, Alan B ^b   Chapman, Judith Anne W ^c   Anborgh, Pieter H ^b   Postenka, Carl O ^b   Al Katib, Waleed ^b,f   Shepherd, Lois E ^c   Han, Lei ^c   Wilson, Carolyn F ^c   Pritchard, Kathleen I ^d   Pollak, Michael N ^e   Chambers, Ann F ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f AMERICAN UNIVERSITY OF MADABA   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; OCTREOTIDE; OSTEOPONTIN; TAMOXIFEN; TUMOR MARKER;

BLOOD; BREAST NEOPLASMS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OCTREOTIDE; OSTEOPONTIN; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84892666381     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3600     Document Type: Article

References (31)

1. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001, 1:621-632. 10.2174/1566524013363339, 11899236.
2. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004, 90:1877-1881. 10.1038/sj.bjc.6601839, 2410284, 15138464.
3. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 2007, 102:859-868. 10.1002/jcb.21520, 17721886.
4. Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of osteopontin as a clinical cancer marker. Oncol Rep 2011, 25:433-441.
5. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010, 103:861-869. 10.1038/sj.bjc.6605834, 2966627, 20823889.
6. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:1087-1097. 10.1158/1055-9965.EPI-06-1008, 17548669.
7. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998, 79:502-508. 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3, 9761120.
8. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002, 62:3417-3427.
9. Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R, Rudland PS. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 2006, 66:1199-1207. 10.1158/0008-5472.CAN-05-2605, 16424059.
10. de Silva Rudland S, Martin L, Roshanlall C, Winstanley J, Leinster S, Platt-Higgins A, Carroll J, West C, Barraclough R, Rudland P. Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res 2006, 12:1192-1200. 10.1158/1078-0432.CCR-05-1580, 16489073.
11. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997, 3:605-611.
12. Bautista DS, Saad Z, Chambers AF, Tonkin KS, O'Malley FP, Singhal H, Tokmakejian S, Bramwell V, Harris JF. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 1996, 29:231-239. 10.1016/0009-9120(96)84728-A, 8740509.
13. Bautista DS, Xuan JW, Hota C, Chambers AF, Harris JF. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 1994, 269:23280-23285.
14. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006, 12:3337-3343. 10.1158/1078-0432.CCR-05-2354, 16740755.
15. Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol 2011, 29:3869-3876. 10.1200/JCO.2010.33.7006, 21911723.
16. Anborgh PH, Wilson SM, Tuck AB, Winquist E, Schmidt N, Hart R, Kon S, Maeda M, Uede T, Stitt LW, Chambers AF. New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. Clin Chem 2009, 55:895-903. 10.1373/clinchem.2008.117465, 19325010.
17. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993, 85:200-206. 10.1093/jnci/85.3.200, 8423624.
18. Bacus S, Flowers JL, Press MF, Bacus JW, McCarty KS. The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. Am J Clin Pathol 1988, 90:233-239.
19. Lipton A, Chapman JA, Demers L, Shepherd LE, Han L, Wilson CF, Pritchard KI, Leitzel KE, Ali SM, Pollak M. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol 2011, 29:3605-3610. 10.1200/JCO.2010.31.5069, 21859992.
20. Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers AF. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem 1995, 57:680-690. 10.1002/jcb.240570413, 7542253.
21. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999, 18:4237-4246. 10.1038/sj.onc.1202799, 10435636.
22. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, Chambers AF. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997, 121:578-584.
23. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996, 88:1456-1466. 10.1093/jnci/88.20.1456, 8841020.
24. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012, 9:e1001216. 10.1371/journal.pmed.1001216, 3362085, 22675273.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072. 10.1200/JCO.2004.01.0454, 16172462, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.
26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
27. Boudjadi S, Bernatchez G, Beaulieu JF, Carrier JC. Control of the human osteopontin promoter by ERRalpha in colorectal cancer. Am J Pathol 2013, 183:266-276. 10.1016/j.ajpath.2013.03.021, 23680656.
28. Vanacker JM, Pettersson K, Gustafsson JA, Laudet V. Transcriptional targets shared by estrogen receptor- related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. EMBO J 1999, 18:4270-4279. 10.1093/emboj/18.15.4270, 1171503, 10428965.
29. El-Tanani M, Fernig DG, Barraclough R, Green C, Rudland P. Differential modulation of transcriptional activity of estrogen receptors by direct protein-protein interactions with the T cell factor family of transcription factors. J Biol Chem 2001, 276:41675-41682. 10.1074/jbc.M103966200, 11522780.
30. Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, Chadwick K, Milosevic M, Catton C, Pintilie M, Chambers AF, Bristow RG. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer 2012, 107:840-846. 10.1038/bjc.2012.345, 3425969, 22871886.
31. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001, 7:4060-4066.